Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, B-Cell
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, B-Cell
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, B-Cell
Description
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. MeSH
Hierarchy View
Subtype Terms (6)
Burkitt Lymphoma
164 drugs (96 approved, 68 experimental)
Lymphoma, AIDS-Related
41 drugs (30 approved, 11 experimental)
Lymphoma, B-Cell, Marginal Zone
222 drugs (114 approved, 108 experimental)
Lymphoma, Large B-Cell, Diffuse
443 drugs (183 approved, 260 experimental)
Lymphoma, Primary Effusion
14 drugs (11 approved, 3 experimental)
Lymphomatoid Granulomatosis
80 drugs (54 approved, 26 experimental)
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (16)
Phase 2 Indicated Drugs (87)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous hematopoietic stem cells
bone marrow derived mesenchymal stem cells
brentuximab vedotin (adcetris)
cord blood hematopoietic stem cell
ibritumomab tiuxetan (Zevalin)
inotuzumab ozogamicin (besponsa)
Phase 1 Indicated Drugs (108)
allogeneic gamma-delta t cells
anti-cd19 and anti-cd20 bicistronic car t- cells
anti-cd19/cd20/cd22 car t-cells
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
cd19/cd20 bispecific car-t cells
cd19-cd34 car transduced t cells
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (102)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Blood and Marrow Transplant Clinical Trials Network
Center for International Blood and Marrow Transplant Research
Centre Hospitalier Schaffner France
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Children's Cancer Group, China
Chinese Academy of Medical Sciences
Chinese Anti-Cancer Association
Fondazione Italiana Diabete Onlus
German High-Grade Non-Hodgkin's Lymphoma Study Group
Huazhong University of Science and Technology
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Laboratorio Elea S.A.C.I.F. y A.
Moorgreen Hospital, Southampton
Nanjing Yoko Biomedical Co., Ltd.
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Organization Involved with Phase 2 Indications (327)
Academic and Community Cancer Research United
Apogee Biotechnology Corporation
Assistance Publique - Hôpitaux de Paris
Azienda Ospedaliera San Giovanni Battista
Beijing Biohealthcare Biotechnology Co.,Ltd
Beijing InnoCare Pharma Tech Co., Ltd.
British Columbia Cancer Agency
Cantonal Hospital of St. Gallen
Case Western Reserve University
Centro di Riferimento Oncologico - Aviano
Chongqing Precision Biotech Co., Ltd
Clinica Universidad de Navarra
Consortium for Improving Survival of Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Dynavax Technologies Corporation
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
Foshan First People's Hospital
French Innovative Leukemia Organisation
Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Groupe Hospitalier Public Sud Oise
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Hoosier Cancer Research Network
Hospital Universitario Central de Asturias
Hospital Universitari Son Dureta
HOVON - Dutch Haemato-Oncology Association
Huizhou People's Central Hospital
Icahn School of Medicine at Mount Sinai
ImmunoVaccine Technologies, Inc.
Innovative Cellular Therapeutics Co., Ltd.
Instytut Hematologii i Transfuzjologii, 02-776 Warszawa ul. Indiry Gandhi 14
International Extranodal Lymphoma Study Group
La Jolla Pharmaceutical Company
Medical City Children's Hospital, Dallas
National Cancer Institute, France
National Cheng Kung University
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
North Central Cancer Treatment Group
Oregon Health and Science University
Ospedale S. Giovanni Bellinzona
Pavlov First Saint Petersburg State Medical University
People's Liberation Army of China
Polish Lymphoma Research Group
Quebec Clinical Research Organization in Cancer
Royal Marsden Hospital NHS Trust
Shanghai Longyao Biotechnology Inc., Ltd.
Shanghai YingLi Pharmaceutical Co. Ltd.
Shenzhen Geno-Immune Medical Institute
Southampton University Hospital NHS Foundation Trust
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Taichung Veterans General Hospital
Technical University of Munich
Territorial Hospital Group (GHT) Rance Emeraude
The Alvin and Lois Lapidus Cancer Institute
The Beijing Pregene Science and Technology Company, Ltd.
The Christie NHS Foundation Trust
Translational Research Institute for Metabolism and Diabetes, Florida
Universidad Autonoma de Madrid
Universidad Autonoma de Nuevo Leon
Universidad Complutense de Madrid
University Hospital Plymouth NHS Trust
University of California, Los Angeles
University of California, San Francisco
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Illinois at Chicago
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Picardie Jules Verne
University of Roma La Sapienza
University of Southern California
University of Texas at Houston
University of Texas, San Antonio
University of Western Brittany
Vita-Salute University of Milano. Italy
Washington University in St. Louis
Organization Involved with Phase 1 Indications (104)
Aeon Therapeutics (Shanghai) Co., Ltd.
Allife Medical Science and Technology Co., Ltd.
Beijing GD Initiative Cell Therapy Technology Co.，Ltd.
Beijing Mabworks Biotech Co., Ltd.
Boryung Pharmaceutical Company
California Institute for Biomedical Research
Cancer and Leukemia Group B (CALGB)
Curon Biopharmaceutical (Australia) Co Pty Ltd
Damon Runyon Cancer Research Foundation
Generon (Shanghai) Corporation Ltd.
Hangzhou HeZheng Pharmaceutical Co., Ltd
Henan Hualong Biotechnology Company
Illawarra Cancer Care Centre (Wollongong)
Malaghan Institute of Medical Research
Marino Biotechnology Co., Ltd.
Medical University of South Carolina
Methodist Cancer Center, Houston, Texas
Nanjing Bioheng Biotech Co., Ltd.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Olivia Newton-John Cancer Research Institute
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Shanghai Celluar Biopharmaceutical Group Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd
Shijiazhuang Pharma Group (CSPC)
The Jewish General Hospital, Montreal QC, Canada
Triphase Research and Development Corporation
Union Stem Cell & Gene Engineering Co.LTD
University of California, Davis
University of California, San Diego
Wellington Zhaotai Therapies Limited
Organization Involved with Other Experimental Indications (11)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
